NCT01262235已完成1 期
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 8
- 主要终点
- Determine dose-limiting toxicities and maximum tolerated dose of TKM-080301
研究概览
简要总结
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologically and cytologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy, or non-Hodgkin's lymphoma or Hodgkin's disease that is refractory to standard therapy (i.e., patients have relapsed following at least 2 prior therapies) or for which no standard therapy is known to exist. For the Neuroendocrine (NET) and adrenocortical carcinoma (ACC) expansion cohort subjects must have histologically or cytologically confirmed, measurable (per RECIST 1.1) NET or ACC tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy.
- •Patient has an ECOG performance status of 0 - 1,
- •Patient has adequate hematologic, hepatic and renal function,
- •Patient is seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV),
- •Patients must have a life expectancy of at least 12 weeks.
排除标准
- •Unresolved toxicities (> Grade 1) of previous chemotherapy,
- •Patients with primary tumors of the central nervous system (CNS),
- •Prophylactic hematologic growth factors administered </= 2 weeks prior to start of therapy,
- •Patient has history of or existing clinically significant cardiovascular disease,
- •Patient has a history of clinically significant asthma or COPD requiring daily medication within the last 6 months,
- •Patient has a seizure disorder not controlled on medication,
- •Patient has a known or suspected viral, parasitic, or fungal infection,
- •Patient has known hypersensitivity or previous severe reactions to oligonucleotide- or lipid-based products, including liposomal drug products and phospholipid-based products,
- •Patient has been treated with any investigational drugs, biologics, or devices within 28 days prior to study treatment.
研究组 & 干预措施
TKM-080301
Experimental
干预措施: TKM-080301 (Drug)
结局指标
主要结局
Determine dose-limiting toxicities and maximum tolerated dose of TKM-080301
时间窗: 6 months
Safety and tolerability of treatment with TKM-080301
时间窗: 6 months
次要结局
- Characterize the pharmacokinetics of TKM-080301(2 months)
- Assess preliminary evidence of anti-tumor activity(6 months)
研究者
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastomaMelanoma Stage IVBrain CancerMetastatic MelanomaMelanoma RecurrentBreast CancerProstate CancerMetastatic Breast CancerGBMProstate Cancer MetastaticNewly Diagnosed GlioblastomaRecurrent GlioblastomaMetastatic Prostate CancerGlioblastoma MultiformeNCT04478279Sapience Therapeutics125
进行中（未招募）
2 期
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsAdvanced Solid TumorsCRPCmCRPCMetastatic Castrate-resistant Prostate CancerPT-112Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteProstatic NeoplasmsNCT02266745Promontory Therapeutics Inc.109
已完成
1 期
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological DisordersAdvanced Hematological DisordersNCT03048344Orsenix LLC12
终止
1 期
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)NeoplasmsNCT00954512Merck Sharp & Dohme LLC15
已完成
1 期
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Bladder CancerNCT05375903UroGen Pharma Ltd.51